10 August 2020 - Diurnal Group announces that Alkindi (hydrocortisone granules in capsules for opening) has been approved by the Australian Therapeutic Goods Administration as a "replacement therapy of adrenal insufficiency" with no age restriction. 

Diurnal anticipates the first sales in Australia will be in H2 2021 following completion of pricing and market access activities.

In Australia and New Zealand, Diurnal is partnered with Emerge Health (recently acquired by Chiesi Farmaceutici, a privately owned Italian pharmaceutical company with a broad global footprint) to pursue market and distribution efforts for Alkindi and Chronocort (modified release hydrocortisone), the Company's second product in development for adults with diseases of cortisol deficiency.

Read Diurnal press release